Sangui Bio Tech International Inc.

EANS-News: Sangui Bio Tech International Inc.
SastoMed starts Granulox sales today

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information/Sales start

Subtitle: Ambitious sales targets, detailed marketing plan, focused sales team

Witten, Germany, April 16, 2012 (euro adhoc) - Subsequent to the granting of the
CE mark authorizing production, distribution and sales in the member countries
of the European Union, and after fifteen months of intensive strategic and
operational preparation, global licensee SastoMed GmbH has initiated sales of
Granulox today on the official approval of the first batch of products.
Granulox, a spray aiming at improved healing of chronic wounds, is based on a
patent by SanguiBioTech GmbH. It currently is the only therapeutic which can
help to soothe the problem of hypoxia i.e. the lack of oxygen supply to chronic
wounds. Indications as granted by the CE mark include diabetic foot, leg ulcer
and decubitus ulcer.
"It is worth noticing", SastoMed Managing Director Michael Sander emphasized,
"that thanks to our highly focused approach and diligent professional work we
managed to obtain the CE mark ahead of our 2010 schedule but are fully prepared
now for a head start into actual commercialization. This was our goal from the
beginning and this first part of the mission was fully accomplished."
According to information provided by the joint venture company, SastoMed GmbH
over the past months hired and trained a sales team of experienced wound
management experts who will now take care of the German market. They will be
supported by additional sales representatives. The sales team is focused on
Granulox exclusively. In the course of premarketing activities multiple contacts
among hospitals, wound ambulances and wound care practitioners have already been
made aware of the advantages of Granulox. Based on the reaction by numerous
experts, SastoMed, therefore, is pursuing ambitious sales targets and expects to
having gained a 10% share of the market for modern wound treatment by the end of
The detailed marketing plan for the current year includes advertisement
campaigns in specialized trade media, noticeable presence at key wound
management conferences, congresses and medical trade fairs including booths,
hosting of workshops and round table sessions as well as lectures and
presentations, both in Germany and on an international level. Negotiations are
underway with potential distributors in key European countries, SastoMed
SastoMed also indicated that production capacity was contractually secured to
meet demand beyond the current ambitious sales targets. Additional market
assumptions and revenue expectations are to be disclosed at some later point in
time after the launch phase of the sales initiatives.
SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech
International, Inc. ( SGBI)

Further inquiry note:
Dr. Joachim Fleing
Fon: +49 (160) 741 27 17
Fax: +49 (2302) 915 191

end of announcement                               euro adhoc 

company:     Sangui Bio Tech International Inc.
             Alfred-Herrhausen-Strasse 44
             D-58455 Witten
phone:       +49(0)2302 915-200
FAX:         +49(0)2302 915-191
sector:      Biotechnology
ISIN:        DE0000906757
stockmarkets: free trade: Hamburg, New York 
language:   English

Weitere Meldungen: Sangui Bio Tech International Inc.

Das könnte Sie auch interessieren: